AnaptysBio is now a focused royalty management company, with its value tied primarily to Jemperli ro

AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) rose 5.3% during mid-day trading on Friday. The co

GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal c

U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates

HC Wainwright & Co. analyst Joseph Pantginis assumes AnaptysBio (NASDAQ:ANAB) with a Buy rati

Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sec

The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical

After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indica

UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target

Barclays analyst Etzer Darout maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the

AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(1.84) per share which missed the analyst con

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on ma

AnaptysBio, Inc. (NASDAQ:ANAB), a company focused on managing the financial collaborations for Jempe

SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on ma

Does AnaptysBio, Inc. (ANAB) have what it takes to be a top stock pick for momentum investors? Let's

Here is how AnaptysBio, Inc. (ANAB) and Coherus Oncology (CHRS) have performed compared to their sec

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on ma

Piper Sandler analyst Yasmeen Rahimi maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and low

WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today a

Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a like

Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and

AnaptysBio shares jump 12% after a favorable Delaware Court ruling in the Tesaro dispute. See the la

AnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earn

U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq

AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest tre

GSK PLC's (LSE:GSK, NYSE:GSK) oncology subsidiary TESARO has secured a partial legal victory after a

Ruling preserves current contracted royalty rates and rejects Tesaro's request for any royalty r

Ruling preserves current contracted royalty rates and rejects Tesaro's request for any royalty reduc

Barclays analyst Etzer Darout maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the

UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target

Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunc

SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management

AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) Director John Schmid sold 20,645 shares of the fir

Piper Sandler analyst Yasmeen Rahimi maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and rai

HC Wainwright & Co. analyst Emily Bodnar reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and m

AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has authorized a Stock R

UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target

Wedbush analyst Martin Fan maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and raises the p

Truist Securities analyst John Lee maintains AnaptysBio (NASDAQ:ANAB) with a Hold and raises the

Stifel analyst Alex Thompson maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price t

Barclays analyst Etzer Darout maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the

HC Wainwright & Co. analyst Emily Bodnar maintains AnaptysBio (NASDAQ:ANAB) with a Buy and ra

AnaptysBio (NASDAQ:ANAB) reported quarterly earnings of $1.58 per share which beat the analyst conse

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innova

Barclays analyst Etzer Darout maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the

AnaptysBio asks a Delaware court to dismiss Tesaro's breach claim, citing anti-SLAPP law in a di

AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovat

Barclays analyst Etzer Darout maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the